Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia

Atherosclerosis

Volumn 173, Issue 1, 2004, Pages 55-68

  Civeira, Fernando ^a   Pocoví, Miguel ^b   Alegría, Eduardo ^b   Alonso, Rodrigo ^b   Carmena, Rafael ^b   Casasnovas, Jose A ^b   Defesche, Joep C ^b   Jensen, Henrik K ^b   Hopkins, Paul N ^b   Illingworth, D Roger ^b   Luengo, Emilio ^b   Masana, Luis ^b   Mata, Pedro ^b   Pérez Jiménez, Francisco ^b   Schaefer, Ernst J ^b   Thompson, Gilbert R ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b NONE

Author keywords

Familial hypercholesterolemia; Guidelines; Management; Treatment

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PITAVASTATIN; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; APHERESIS; B SCAN; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RISK; DEATH; DIAGNOSTIC PROCEDURE; DIET THERAPY; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EXERCISE TEST; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; HETEROZYGOTE; HUMAN; INTRAVASCULAR ULTRASOUND; LIFESTYLE; LIPID ANALYSIS; LIPOPROTEIN METABOLISM; MONOGENIC DISORDER; MONOTHERAPY; NUTRIENT; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; RELATIVE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SIDE EFFECT; SMOKING CESSATION; TENDON DISEASE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; XANTHOMA;

EID: 10744233618     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.11.010     Document Type: Article

References (117)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease, vol. 120. New York: McGraw-Hill; 2001. p. 2863-913.
2. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
3. Goldstein J.L., Brown M.S. The cholesterol quartet. Science. 292:2001;1310-1312.
4. Pullinger C.R., Eng C., Salen G.et al. Human cholesterol 7 alpha hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110:2002;109-117.
5. Innerarity T.L., Mahley R.W., Weisgraber K.H., Bersot T.P., Krauss R.M., Vega G.L.et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J. Lipid Res. 31:1990;1337-1349.
6. Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 104:1993;1-18.
7. Varret M., Rabes J.P., Saint-Jore B., Cenarro A., Marinoni J.C., Civeira F.et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am. J. Hum. Genet. 64:1999;1378-1387.
8. Hunt S.C., Hopkins P.N., Bulka K., McDermott M.T., Thorne T.L., Wardell B.B.et al. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler. Thromb. Vasc. Biol. 20:2000;1089-1093.
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307.
11. Sacks F.M., Pfeffer M.A., Moye S.A., Rouleau J.L., Rutherford J.D., Cole T.G.et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
12. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary Heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
13. Downs J.R., Clearfield M., Weis S.et al. Primary Prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
14. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
15. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999;142:105-12.
16. WHO. Human Genetic Program. Familial Hypercholesterolemia, report of a WHO consultation. WHO/HGN/FH/CONS/98.7 Paris; October 1997.
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
18. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.
19. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk categories. Circulation. 97:1998;1837-1847.
20. Assmann G., Cullen P., Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur. Heart J. 19(Suppl A):1998;A2-A11.
21. Scientific Steering Committee (SSC) on behalf of the Simon Broome register Group. Risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ 1991;303:893-6.
22. Goldman L., Goldman P.A., Williams L.W., Weinstein M.C. Cost effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am. J. Cardiol. 72:1993;75D-79D.
23. Moorjani S., Roy M., Gagné C., Davignon J., Brun D., Toussaint M.et al. Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis. 9:1989;211-216.
24. Kotze M.J., De Villiers W.J.S., Steyn K., Kriek J.A., Marais A.D., Langenhoven E.et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler. Thromb. 13:1993;1460-1468.
25. Gylling H., Aalto-Setälä K., Kontula K., Miettinen T.A. Serum low-density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low-density lipoprotein receptor gene in familial hypercholesterolemia. Arterioscler. Thromb. 11:1991;1368-1375.
26. Hirobe K., Matsuzawa Y., Ishikawa K.et al. Coronary artery disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 44:1982;201-210.
27. Hill J.S., Hayden M.R., Frohlich J., Pritchard P.H. Genetic and enviromental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler. Thromb. 11:1991;290-297.
28. Gagné C., Moorjani S., Brun D., Toussaint M., Lupien P.J. Heterozygous familial hypercholesterolemia. Atherosclerosis. 34:1979;13-24.
29. Alonso R., Castillo S., Civeira F., Puzo J., La Cruz J.J., Pocovi M.et al. Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases. Med. Clin. (Barc). 118:2002;487-492.
30. Koivisto U.M., Hamalainen L., Taskinen M.R., Kettunen K., Kontula K. Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. J. Lipid Res. 34:1993;269-277.
31. Baron H., Fung S., Aydin A., Bahring S., Luft F.C., Schuster H. Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia. Nat. Biotechnol. 14:1996;1279-1282.
32. Schuster H. High risk/high priority: familial hypercholesterolemia - a paradigm for molecular medicine. Atherosclerosis 2002;(Suppl 2):27-32.
33. Mabuchi H, Koizumi J, Shimuzu M, Takeda R, Hokuriku FH, CHD Study Group. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225-32.
34. Miettinen T., Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Arteriosclerosis. 8:1988;163-167.
35. Gotto A.M. Jr. Management of dyslipidemia. Am. J. Med. 112(Suppl 8A):2002;10S-18S.
36. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:1990;3007-3012.
37. Tatami R., Inoue N., Itoh H., Kishino B., Koga N., Nakashima Y.et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis. 95:1992;1-13.
38. Nishimura S., Sekiguchi M., Kano T., Ishiwata S., Nagasaki F., Nishide T.et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 144:1999;409-417.
39. Kroon A.A., Aengevaeren W.R., van der Werf T., Uijen G.J., Reiber J.H., Bruschke A.V.et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835.
40. Thompson G.R., Maher V.M., Matthews S., Kitano Y., Neuwirth C., Shortt M.B.et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816.
41. Matsuzaki M., Hiramori K., Imaizumi T., Kitabatake A., Hishida H., Nomura M.et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J. Am. Coll. Cardiol. 40:2002;220-227.
42. Pitsavos C.E., Aggeli K.I., Barbetseas J.D., Skoumas I.N., Lambrou S.G., Frogoudaki A.A.et al. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 82:1998;1484-1488.
43. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581.
44. Alonso R., Mata P., De Andres R., Villacastin B.P., Martinez-Gonzalez J., Badimon L. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis. 157:2001;423-429.
45. Aengevaeren W.R., Kroon A.A., Stalenhoef A.F., Uijen G.J., van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J. Am. Coll. Cardiol. 28:1996;1696-1704.
46. Descamps O., Leysen X., Van Leuven F.et al. The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. Atherosclerosis. 157:2001;514-518.
47. Williams R., Hunt S., Schumacher C.et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72:1993;171-176.
48. Defesche J. Familial hypercholesterolemia. In: Betteridge J, editor. Lipids and vascular disease, vol. 6. London: Martin Dunitz; 2000. p. 65-76.
49. Marks D., Wonderling D., Thorogood M., Lambert H., Humphries E., Neil A.W. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolemia. BMJ. 324:2002;1303-1308.
50. Ferrieres J., Lambert J., Lussier-Cacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 92:1995;290-295.
51. Hopkins P., Stephenson S., Wu L., Riley W.A., Xin Y., Hunt S.C. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 87:2001;547-553.
52. Seed M., Hoppichler F., Reaveley D., McCarthy S., Thompson G.R., Boerwinkle E.et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl. J. Med. 322:1990;1494-1499.
53. Tonstad S., Joakimsen O., Stensland-Bugge E., Leren T.P., Ose L., Russell D.et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler. Thromb. Vasc. Biol. 16:1996;984-991.
54. Wittekoek M.E., de Groot E., Prins M.H., Trip M.D., Büller H.R., Kastelein J.J. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis. 146:1999;271-279.
55. Bertolini S., Cantafora A., Averna M., Cortese C., Motti C., Martini S. et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler. Thromb. Vasc. Biol. 20:2000;E41-E52.
56. Smilde T.J., van Wissen S., Wollersheim H., Kastelein J.J., Stalenhoef A.F. Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia. Neth. J. Med. 59:2001;184-195.
57. Taira K., Bujo H., Kobayashi J., Takahashi K., Miyazaki A., Saito Y. Positive family history for coronary heart disease and 'midband lipoproteins' are potential risk factors of carotid atherosclerosis in familial hypercholesterolemia. Atherosclerosis. 160:2002;391-397.
58. Real J.T., Chaves F.J., Ascaso J.F., Carmena R. Importance of HDL cholesterol levels and total to HDL cholesterol ratio as risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolemia. Eur. Heart. J. 22:2001;465-471.
59. Lundahl B., Leren T.P., Ose L., Hamsten A., Karpe F. A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP-493G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20:2000;1784-1788.
60. Wittekoek M.E., Moll E., Pimstone S.N., Trip M.D., Lansberg P.J., Defesche J.C.et al. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 19:1999;2708-2713.
61. Wittekoek M.E., Pimstone S.N., Reymer P.W., Feuth L., Botma G.J., Defesche J.C.et al. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation. 97:1998;729-735.
62. Carmena-Ramon R., Ascaso J.F., Real J.T., Najera G., Ordovas J.M., Carmena R. Association between the TaqIB polymorphism in the CETP gene locus and plasma lipoprotein levels in familial hypercholesterolemia. Metabolism. 50:2001;651-656.
63. Cenarro A., Artieda M., Castillo S., Mozas P., Reyes G., Tejedor D.et al. A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. J. Med. Genet. 40:2003;163-168.
64. Jansen A.C., van Wissen S., Defesche J.C., Kastelein J.J. Phenotypic variability in familial hypercholesterolemia: an update. Curr. Opin. Lipidol. 13:2002;165171.
65. Gidding S.S., Bookstein L.C., Chomka E.V. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation. 98:1998;2580-2583.
66. Mabuchi H., Koizumi J., Shimizu M.et al. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 79:1989;225-232.
67. Grundy S.M., Pasternack R., Greenland P., Smith S., Fuster V. Assessment of cardiovascular risk by use of multiple risk factor assessment equations. Circulation. 100:1999;1.481-1.492.
68. Arruda A.M., Das M.K., Roger V.L., Klarich K.W., Mahoney D.W., Pellikka P.A. Prognostic value of exercise echocardiography in 2.632 patients > or = 65 years of age. J. Am. Coll. Cardiol. 37:2001;1.036-1.041.
69. O'Rourke R.A., Brundage B.H., Froelicher V.F., Greenland P., Grundy S.M., Hachamovitch R.et al. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation. 102:2000;126-140.
70. Sacks D., Bakal C.W., Beatty P.T., Becker G.J., Cardella J.F. Position statement of the use of the ankle-brachial index in the evaluation of patients with peripheral vascular disease: a consensus statement developed by the standards division of the Society of Cardiovascular, Position statement of the use of the ankle-brachial index in the evaluation of patients with peripheral vascular disease: a consensus statement developed by the standards division of the Society of Cardiovascular & Interventional Radiology. J. Vasc. Interv. Radiol. 13:2002;353.
71. Barth J.D. An update on carotid ultrasound measurement of intima-media thickness. Am. J. Cardiol. 89(Suppl 4A):2002;32B-39B.
72. Wilmink A.B., Hubbard C.S., Day N.E., Quick C.R. The incidence of small abdominal aortic aneurysms and the change in normal infrarenal aortic diameter: implications for screening. Eur. J. Vasc. Endovasc. Surg. 21:2001;165-170.
73. Feinstein S.B., Voci P., Pizzuto F. Noninvasive surrogate markers of atherosclerosis. Am. J. Cardiol. 89(Suppl 5A):2002;31C-44C.
74. Thompson G.R., Hollyer J., Waters D.D. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr. Opin. Lipidol. 6:1995;386-388.
75. Thompson G.R. What targets should lipid-modulating therapy achieve to optimize the prevention of coronary heart disease? Atherosclerosis. 131:1997;1-5.
76. Pearson T., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project. Arch Intern. Med. 160:2000;459-467.
77. de Lorgeril M., Renaud S., Mamelle N., Salen P., Martín J.L., Monjaud I.et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 343:1994;1454-1459.
78. Mensink M., Katan M. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler. Thromb. 12:1992;911-919.
79. Perez-Jimenez F., Lopez-Miranda J., Mata P. Protective effect of dietary monosaturated fat on arteriosclerosis: beyond cholesterol. Atherosclerosis. 163:2002;385-398.
80. Cleghorn C.L., Skeaff C.M., Mann J., Chisholm A. Plant sterol-enriched spread enhances the cholesterol-lowering potencial of a fat-reduced diet. Eur. J. Clin. Nutr. 57:2003;170-176.
81. Ling W.H., Jones P.J. Dietary phytosterol: a review of metabolism, benefits, and side effects. Life Sci. 57:1995;195-206.
82. Kris-Etherton P.M., Hecker K.D., Bonanome A., Coval S.M., Binkoski A.E., Hilpert K.F.et al. Bioactive compounds in foods: their role in the prevention of cardiovascular dosease and cancer. Am. J. Med. 113(9B):2002;71S-88S.
83. Sugano M., Morioka H., Ikeda I. A comparison of hypocholesterolemic activity of beta-sitosterol and beta-sitostanol in rats. J. Nutr. 107:1977;2011-2019.
84. Amundsen A.L., Ose L., Nenseter M.S., Ntanios F. Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am. J. Clin. Nutr. 76:2002;338-344.
85. Gylling H., Siimes M.A., Miettinen T.A. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J. Lipid Res. 36:1995;1807-1812.
86. Ketomaki A., Gylling H., Siimes M.A., Vuorio A., Miettinen T.A. Squalene and noncholesterol sterols in serum and lipoproteins of children with and without familial hypercholesterolemia. Pediatr. Res. 53:2003;1-6.
87. Miettinen T.A., Gylling H., Lindbohm N., Miettinen T.E., Rajaratnan R.A., Relas H. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J. Lab. Clin. Med. 141:2003;131-137.
88. Sudhop T., Gottwald B.M., von Bergmann K. Serum plant sterols as a potential risk factor for coronary disease. Metabolism. 51:2002;1519-1521.
89. Mustaad V., Kris-Etherton P.M. Beyond cholesterol lowering: deciphering the benefits of dietary intervention on cardiovascular diseases. Curr. Atherocler. Rep. 2:2000;461-466.
90. Sudhop T., Lütjohann D., Kodal A., Igel M., Tribble D.L., Shah S.et al. Inhibition of intestinal cholesterol absortion by ezetimibe in humans. Circulation. 106:2002;1943-1948.
91. Schneck D.W., Knopp R.H., Ballantyne C.M., McPherson R., Chitra R.R., Simonson S.G. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol. 91:2003;33-41.
92. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E.et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 93:2003;152-160.
93. Blasetto J.W., Stein E.A., Brown W.V., Chitra R., Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am. J. Cardiol. 91(suppl):2003;3C-10C.
94. Insull W. Jr., Marquis N.R., Tsianco M.C. Comparison of the efficacy of questran light, a new formulation of colestyramine powder, to regular questran in maintaining lowered plasma cholesterol levels. Am. J. Cardiol. 67:1991;501-505.
95. Hunninghake D.B., Stein E.A., Bremner W.F., Greenland P., Demke D.M., Oliphant T.H. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am. J. Ther. 2:1995;180-189.
96. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993;153:1321-9.
97. Insull W. Jr., Toth P., Mullican W., Hunninghake D., Burke S., Donovan J.M.et al. Effectiveness of colesevelam hydrochloride in decreasing LDL colesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trail. Mayo Clin. Proc. 76:2001;971-982.
98. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al., Esetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absortion inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7.
99. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P.et al. Ezetimibe coadministered with simvastatin inpatients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40:2002;2125-2134.
100. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, et al., Ezetimibe Study Group. Efficacy and safety of eztimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
101. Mata P., Alonso R., Badimon J.J. Risk-benefit assessment of simvastatin in patients with familial hypercholesterolemia. Drug Saf. 26:2003;769-786.
102. Roberts W.C. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol. 82:1997;106-107.
103. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
104. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81:1998;582-587.
105. McCrindle B.W., Helden E., Cullen-Dean G., Conner W.T. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pedriatr. Res. 51:2002;715-721.
106. Hagen E., Istad H., Ose L., Bodd E., Eriksen H.M., Selvig V.et al. Fluvastatin efficacy and tolerability in comparison and in combination with colestyramine. Eur. J. Clin. Pharmacol. 46:1994;445-449.
107. Davidson M.H. Combination therapy for dyslipidemia: safety and regulatory considerations. Am. J. Cardiol. 90(suppl):2002;50K-60K.
108. Leiteredorf E., Muratti E.N., Eliav O., Peters T.K. Effciacy and safty of triple therapy (Fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolaemia. Am. J. Cardiol. 76:1995;84A-88A.
109. Stein E.A., Illingworth D.R., Kwiterovich P.O. Jr., Liacouras C.A., Siimes M.A., Jacobson M.S.et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 281:1999;137-144.
110. De Jongh S., Ose L., Szamosi T., Gagne C., Lambert M., Scott R.et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 106:2002;2231-2237.
111. Gordon B.R., Saal S.D. Current status of low density lipoprotein- apheresis for the therapy of severe hyperlipidemia. Curr. Opin. Lipidol. 7:1996;381-381.
112. Schmaldienst S., Banyai S., Stulnig Th.M., Heinz G., Jansen M., Hörl W.H.et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolemia. Atherosclerosis. 151:2000;493-499.
113. Bambauer R. Low-density lipoprotein apheresis: clinical results with different methods. Artif. Organs. 26:2002;133-139.
114. Hudgins L.C., Gordon B.R., Parker T.S., Saal S.D., Levine D.M., Rubin A.L. LDL apheresis: an effective and safe treatment for refractory hypercholesterolemia. Cardiovasc. Drug Rec. 20:2002;271-280.
115. Barter P.J. Coronary plaque regression: role of low density lipoprotein-apheresis. J. Am. Coll. Cardiol. 40:2002;228-230.
116. Thompson G.R. LDL apheresis. Atherosclerosis. 167:2003;1-13.
117. Cashin-Hemphill L, Noone M, Abbott JF, Waksmonski CA, Lees RS. Low-density lipoprotein apheresis therapy during pregnancy. Am J Cardiol 2000;86:1160, A10.